The Clorox Company
NYSE:CLXHousehold & Personal Products
-$2.54 today
- Market cap
- $13.13B
- Beta
- 0.55
- P/E (TTM)
- 15.2
- EPS (TTM)
- $6.23
- Dividend yield
- 5.22%
Volume 2.16M
Average 2.84M
CLX Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
The Clorox CompanyNYSE: CLX
Revenue · Q1 FY2027 · quarter ended Sep 2026
Revenue growth accelerates
Q1 FY2027 revenue of $1.91B rose 33.3% year over year, ahead of the +6.3% change in trailing-twelve-month revenue. Sequentially, it fell 2.2% from the prior quarter. Over 3 fiscal years it compounded at -3.1% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 12 analysts of $7.64B (+13.7%) for the fiscal year ending Jun 2027, a step up from the -5.4% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $1.91B-2.2% QoQ
- Last fiscal yearJun 2026
- $6.72B-5.4% YoY
- LTMSep 2026
- $7.2B+6.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +33.3% | +11.9% | -21.4 pp |
| 1 year | -5.4% | +13.7% | +19.1 pp |
| 3-year CAGR | -3.1% | +6.0% | +9.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2026
- 6.72B USD
- Year-over-year change
- -5.4%
- 4-year CAGR
- -1.4%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 6.72B | -5.4% |
| FY2025 | 2025-06-30 | 7.1B | +0.2% |
| FY2024 | 2024-06-30 | 7.09B | -4.0% |
| FY2023 | 2023-06-30 | 7.39B | +4.0% |
| FY2022 | 2022-06-30 | 7.11B | — |
Revenue vs competitors
How CLX compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +6.3% is the highest of 11, against a peer median of +1.3%.
- Over three fiscal years its annual growth of -3.1% compares with a peer median of -0.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $87.92B USD | +3.5% | +2.0% | |
| FY2025 | €50.5B EUR | -16.9% | -5.6% | |
| LTM Sep 2026 | $21.28B USD | +5.9% | +4.3% | |
| LTM Jun 2026 | $16.57B USD | -8.4% | -5.1% | |
| LTM Sep 2026 | $15.53B USD | +3.5% | +0.4% | |
| LTM Sep 2026 | $7.2B USD | +6.3% | -3.1% | |
| LTM Sep 2026 | $6.25B USD | +1.7% | +4.9% | |
| LTM Jun 2026 | $3.79B USD | +2.7% | -0.8% | |
| LTM Jun 2026 | $2.87B USD | +0.8% | -3.6% | |
| LTM Mar 2026 | $2.11B USD | -5.3% | +0.8% | |
| LTM Feb 2026 | $1.79B USD | -6.4% | -4.8% | |
| Peer median (excluding CLX) | — | +1.3% | -0.2% | |
Competitors are the stored peer set for CLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 7.11B | 7.39B | 7.09B | 7.1B | 6.72B |
| Cost of Revenue | 4.56B | 4.48B | 4.05B | 3.89B | 3.88B |
| Gross Profit | 2.55B | 2.91B | 3.05B | 3.21B | 2.84B |
| Gross Margin | 35.8% | 39.4% | 43.0% | 45.2% | 42.3% |
| Research & Development | 132M | 138M | 126M | 121M | 116M |
| Selling, General & Admin | 1.66B | 1.92B | 2.17B | 1.89B | 1.07B |
| Operating Expenses | 1.83B | 2.09B | 2.33B | 2.04B | 1.18B |
| Depreciation & Amortization | 224M | 236M | 235M | 219M | 247M |
| EBITDA | 937M | 564M | 723M | 1.39B | 1.17B |
| EBITDA Margin | 13.2% | 7.6% | 10.2% | 19.5% | 17.4% |
| Operating Income | 719M | 823M | 723M | 1.18B | 1.66B |
| Operating Margin | 10.1% | 11.1% | 10.2% | 16.6% | 24.7% |
| Interest Income | 5M | 16M | 23M | 9M | 8M |
| Interest Expense | 106M | 90M | 90M | 88M | 130M |
| Other Income / Expenses | (112M) | (585M) | (325M) | (99M) | (871M) |
| Income Before Tax | 607M | 238M | 398M | 1.08B | 791M |
| Pre-Tax Margin | 8.5% | 3.2% | 5.6% | 15.2% | 11.8% |
| Income Tax Expense | 136M | 77M | 106M | 254M | 190M |
| Net Income | 462M | 149M | 280M | 810M | 587M |
| Net Margin | 6.5% | 2.0% | 3.9% | 11.4% | 8.7% |
| EPS (Basic) | 3.75 | 1.21 | 2.25 | 6.56 | 4.82 |
| EPS (Diluted) | 3.73 | 1.20 | 2.25 | 6.52 | 4.81 |
| Weighted Avg Shares | 123.11M | 123.59M | 124.17M | 123.53M | 121.78M |
| Weighted Avg Shares (Diluted) | 123.91M | 124.18M | 124.8M | 124.29M | 122.13M |
The Clorox Company
NYSE:CLX
Intrinsic Alpha fair value
Locked
Current Price
$108.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.